美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

亚盛医药

21.64

-2.0200-8.54%

盘后：21.640.00000.00%16:10 EST

成交量：7,736.00

成交额：16.93万

市值：20.20亿

市盈率：-10.93

高：22.52

开：22.14

低：21.50

收：23.66

52周最高：48.45

52周最低：17.56

股本：9,333.04万

流通股本：7,158.28万

量比：7.97

换手率：0.01%

股息：- -

股息率：- -

每股收益(TTM):-1.9795

每股收益(LYR):-0.7356

净资产收益率：-159.65%

总资产收益率：-22.77%

市净率：20.99

市盈率(LYR):-29.42

数据加载中...

总览公司新闻资讯公告

亚盛医药盘中异动股价大涨6.42%报24.69美元

亚盛医药盘中异动股价大跌5.65%报23.21美元

亚盛医药BTK降解剂APG-3288新药临床申请（IND）获CDE许可，全球临床开发再提速

亚盛医药-B盘中涨超3% BTK降解剂1类新药APG-3288片获批临床

Bloomberg 专访｜亚盛医药董事长杨大俊：聚焦未满足临床需求，践行全球化进阶之路

亚盛医药杨大俊：不追风，走自己的路，让产品说话

丁香园 Insight 数据库

2026年JPM大会诺华、阿斯利康、辉瑞等巨头超百亿美元交易频现，中国资产成最大赢家

药厂那点事儿

JPM2026 | 亚盛医药：多元化管线建设取得突破性进展

医药魔方Info

亚盛医药精彩亮相第44届摩根大通医疗健康年会主会场，“全球创新”战略迈入新阶段

港股异动 | 亚盛医药-B(06855)涨近4% BTK降解剂APG-3288新药临床申请获美国FDA许可

亚盛医药BTK降解剂APG-3288的新药临床申请（IND）获美国FDA许可

亚盛医药-B(06855)：David Sidransky将获委任为首席独立非执行董事

中金:维持亚盛医药-B(06855)“跑赢行业”评级 POLARIS-1欧美获批

【直击2025 ASH】亚盛医药耐立克®治疗TKI耐药/不耐受CML-CP患者的注册II期研究4年随访数据亮相，长期疗效和安全性优势再获证实

【直击2025 ASH】亚盛医药耐立克®二线治疗CML-CP临床研究数据更新，更前线治疗潜力明显

【直击2025 ASH】亚盛医药耐立克®治疗初治Ph+ ALL患者注册III期研究（POLARIS-1）数据国际首发，最佳MRD阴性完全缓解率超60%

亚盛医药的“底牌”

【直击2025 ASH】亚盛医药Bcl-2抑制剂利生妥®治疗维奈克拉经治髓系肿瘤患者的Ib/II期研究数据积极，全球竞争力持续显现

【直击2025 ASH】突破BTKi耐药和复杂核型的困境！亚盛医药口头报告利生妥®中国关键注册研究数据

港股异动 | 亚盛医药-B(06855)涨超6% 耐立克®POLARIS-1研究获美国FDA和欧洲EMA批准

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/AAPG/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亚盛医药","latestPrice":21.64,"timestamp":1772571600000,"preClose":23.66,"halted":0,"volume":7736,"hourTrading":{"tag":"盘后","latestPrice":21.64,"preClose":21.64,"latestTime":"16:10 EST","volume":80,"amount":1731.2,"timestamp":1772572204499,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.08537616229923921,"floatShares":71582800,"shares":93330405,"eps":-1.979486,"marketStatus":"盘后交易","change":-2.02,"latestTime":"03-03 17:02:03 EST","open":22.14,"high":22.52,"low":21.5,"amount":169279.5242,"amplitude":0.043111,"askPrice":23.5,"askSize":100,"bidPrice":21.52,"bidSize":900,"shortable":3,"etf":0,"ttmEps":-1.979486,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772586000000},"marketStatusCode":4,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":23.66,"postHourTrading":{"tag":"盘后","latestPrice":21.64,"preClose":21.64,"latestTime":"16:10 EST","volume":80,"amount":1731.2,"timestamp":1772572204499,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":7.968685},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-22.77%","roe":"-159.65%","lyrEps":-0.735552,"volumeRatio":7.968685,"shares":93330405,"dividePrice":0,"high":22.52,"amplitude":0.043111,"preClose":23.66,"low":21.5,"week52Low":17.555,"pbRate":"20.99","psRate":"35.78","week52High":48.45,"institutionHeld":0,"latestPrice":21.64,"committee":0.8,"eps":-1.979486,"divideRate":0,"volume":7736,"delay":0,"ttmEps":-1.979486,"open":22.14,"prevYearClose":26.24,"prevWeekClose":24.1,"prevMonthClose":24.1,"prevQuarterClose":26.24,"fiveDayClose":25.24,"twentyDayClose":23.17,"sixtyDayClose":30.33},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盘前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1765083600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2026-03-02","current":-10.932131,"percent":1,"low":-76.454813,"twenty":-41.436089,"median":-29.39226,"eighty":-17.078346,"high":-12.575892,"avg":-31.539527,"sd":16.460587,"marketCap":2118279504.36},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4},{"date":"2025-09-12","current":-22.941741,"twenty":-59.475774,"median":-35.943012,"eighty":-31.122625,"marketCap":3735810338.07},{"date":"2025-09-19","current":-21.785524,"twenty":-59.316014,"median":-35.857966,"eighty":-29.943039,"marketCap":3550375801.58},{"date":"2025-09-26","current":-21.102028,"twenty":-59.062646,"median":-35.66937,"eighty":-29.751262,"marketCap":3428719452.06},{"date":"2025-10-03","current":-22.266298,"twenty":-59.025902,"median":-35.30284,"eighty":-28.699054,"marketCap":3625414266.5},{"date":"2025-10-10","current":-21.050291,"twenty":-58.738293,"median":-35.189473,"eighty":-26.732175,"marketCap":3423480133.18},{"date":"2025-10-17","current":-19.80269,"twenty":-58.191808,"median":-34.731922,"eighty":-24.468638,"marketCap":3221889328.22},{"date":"2025-10-24","current":-19.801335,"twenty":-57.904825,"median":-34.477812,"eighty":-23.569995,"marketCap":3222890223.42},{"date":"2025-10-31","current":-19.321494,"twenty":-57.532716,"median":-34.141844,"eighty":-22.943557,"marketCap":3150231208.59},{"date":"2025-11-07","current":-18.112503,"twenty":-56.69325,"median":-33.992043,"eighty":-22.558349,"marketCap":2949090425.48},{"date":"2025-11-14","current":-19.583345,"twenty":-55.920234,"median":-33.485756,"eighty":-22.342071,"marketCap":3199584585.23},{"date":"2025-11-21","current":-17.547753,"twenty":-55.765092,"median":-33.408485,"eighty":-22.122489,"marketCap":2860955000.96},{"date":"2025-11-28","current":-18.539078,"twenty":-55.318442,"median":-33.361942,"eighty":-21.796498,"marketCap":3034915066.08},{"date":"2025-12-05","current":-18.33416,"twenty":-53.27811,"median":-33.187028,"eighty":-21.590149,"marketCap":3005486168.49},{"date":"2025-12-12","current":-17.062052,"twenty":-48.796704,"median":-32.920123,"eighty":-21.073758,"marketCap":2802301628.68},{"date":"2025-12-19","current":-16.188794,"twenty":-48.517949,"median":-32.72391,"eighty":-20.125041,"marketCap":2665447409.6},{"date":"2025-12-26","current":-15.347054,"twenty":-48.514967,"median":-32.664532,"eighty":-19.801335,"marketCap":2537308174.25},{"date":"2026-01-02","current":-14.520508,"twenty":-48.239817,"median":-32.57809,"eighty":-19.656119,"marketCap":2406972911.39},{"date":"2026-01-09","current":-15.636938,"twenty":-46.480698,"median":-32.420873,"eighty":-19.300607,"marketCap":2595562368.02},{"date":"2026-01-16","current":-14.792082,"twenty":-45.997596,"median":-31.846105,"eighty":-19.073232,"marketCap":2461528990.12},{"date":"2026-01-23","current":-14.451393,"twenty":-45.706429,"median":-31.242401,"eighty":-18.892753,"marketCap":2402559084.95},{"date":"2026-01-30","current":-13.594278,"twenty":-43.897892,"median":-30.891003,"eighty":-18.486342,"marketCap":2268064814.82},{"date":"2026-02-06","current":-13.215954,"twenty":-42.7913,"median":-29.979764,"eighty":-18.329609,"marketCap":2208187061.91},{"date":"2026-02-13","current":-13.314281,"twenty":-42.590497,"median":-29.752899,"eighty":-18.136415,"marketCap":2236446544.83},{"date":"2026-02-20","current":-13.322258,"twenty":-42.10164,"median":-29.751262,"eighty":-17.934704,"marketCap":2235292402.77},{"date":"2026-02-27","current":-13.022247,"twenty":-41.475205,"median":-29.511221,"eighty":-17.157024,"marketCap":2206480506.48},{"date":"2026-03-02","current":-12.575892,"twenty":-41.436089,"median":-29.39226,"eighty":-17.078346,"marketCap":2118279504.36}],"updateTime":1772575323313},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611705143","title":"亚盛医药盘中异动 股价大涨6.42%报24.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611705143","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611705143?lang=zh_cn&edition=fundamental","pubTime":"2026-02-14 05:00","pubTimestamp":1771016411,"startTime":"0","endTime":"0","summary":"北京时间2026年02月14日05时00分，亚盛医药股票出现波动，股价大幅上涨6.42%。截至发稿，该股报24.69美元/股，成交量4603股，换手率0.00%，振幅2.31%。亚盛医药股票所在的生物技术行业中，整体涨幅为1.33%。其相关个股中，Moolec Science Sa、Aim Immunotech Inc.、Moolec Science Sa C/Wts 30/01/2028涨幅较大，Moolec Science Sa、Biorestorative Therapies, Inc.、Quince Therapeutics, Inc.较为活跃，换手率分别为6877.68%、357.46%、298.52%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Moolec Science Sa、Aim Immunotech Inc.，振幅分别为174.71%、80.59%、75.94%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260214050011a6f8e96b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260214050011a6f8e96b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG","ASPHF"],"gpt_icon":0},{"id":"2611359651","title":"亚盛医药盘中异动 股价大跌5.65%报23.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611359651","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611359651?lang=zh_cn&edition=fundamental","pubTime":"2026-02-13 04:56","pubTimestamp":1770929785,"startTime":"0","endTime":"0","summary":"北京时间2026年02月13日04时56分，亚盛医药股票出现异动，股价快速下挫5.65%。截至发稿，该股报23.21美元/股，成交量1257股，换手率0.00%，振幅3.17%。最近的财报数据显示，该股实现营业收入32.21百万美元，净利润-81.43百万美元，每股收益-0.95美元，毛利23.92百万美元，市盈率-11.45倍。亚盛医药股票所在的生物技术行业中，整体涨幅为0.32%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213045625a49db8a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213045625a49db8a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG","06855","ASPHF"],"gpt_icon":0},{"id":"2609095558","title":"亚盛医药BTK降解剂APG-3288新药临床申请（IND）获CDE许可，全球临床开发再提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2609095558","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609095558?lang=zh_cn&edition=fundamental","pubTime":"2026-02-06 10:04","pubTimestamp":1770343440,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年2月6日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药宣布，公司自主研发的原创新一代布鲁顿酪氨酸激酶靶向蛋白降解剂APG-3288的新药临床申请日前已获国家药品监督管理局药品审评中心许可，拟开发用于治疗复发/难治性血液系统恶性肿瘤。此前，该药物已获美国FDA许可开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4882324_ZH82324_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1223083913.SGD","LU1223082196.USD","LU1223082519.USD","LU1923622291.USD","CDE","BK1574","BK4129","BK4017","IND","06855","BK4139","TK","LU2125909759.SGD","APG","AAPG","LU2125909916.SGD","BK1161","BK4144"],"gpt_icon":0},{"id":"2608335305","title":"亚盛医药-B盘中涨超3% BTK降解剂1类新药APG-3288片获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2608335305","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608335305?lang=zh_cn&edition=fundamental","pubTime":"2026-02-04 11:08","pubTimestamp":1770174480,"startTime":"0","endTime":"0","summary":"　　亚盛医药-B盘中涨超3%，截至发稿，股价上涨1.38%，报45.88港元，成交额3697.50万港元。公开资料显示，这是亚盛医药研发的新一代BTK靶向蛋白降解疗法。　　APG-3288是亚盛医药自主研发的首个新型高效和高选择性BTK降解剂。临床前研究结果显示，与其他在研BTK降解剂相比，APG-3288具更强的BTK降解能力、更高的选择性及更优越的PK特征，呈现潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-02-04/doc-inhkrihn3096297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["APG","BK4139","BK4129","BK1574","BK1161","06855","LU2125909759.SGD","LU2125909916.SGD","LU1923622291.USD","AAPG"],"gpt_icon":0},{"id":"2604030799","title":"Bloomberg 专访｜亚盛医药董事长杨大俊：聚焦未满足临床需求，践行全球化进阶之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2604030799","media":"亚盛医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604030799?lang=zh_cn&edition=fundamental","pubTime":"2026-01-19 08:40","pubTimestamp":1768783221,"startTime":"0","endTime":"0","summary":"第 44 届JPM会议日前在旧金山盛大召开。亚盛医药董事长、CEO 杨大俊博士，作为拥有近 20 年参会经历的行业见证者，日前接受全球知名财经媒体彭博社专访，分享了亚盛医药的全球化布局与行业发展趋势。亚盛医药已经启动了核心候选药物的多项全球 III 期临床研究，这是极少数中国biotech公司能做到的。亚盛医药已经成立 16 年。我们成功的关键就是聚焦全球未被满足的临床需求，坚持高质量研发，同时在中美两地同步推进临床项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119084610a43a8426&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119084610a43a8426&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","06855","BK1574","BK1161"],"gpt_icon":0},{"id":"2603379009","title":"亚盛医药杨大俊：不追风，走自己的路，让产品说话","url":"https://stock-news.laohu8.com/highlight/detail?id=2603379009","media":"丁香园 Insight 数据库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603379009?lang=zh_cn&edition=fundamental","pubTime":"2026-01-16 07:50","pubTimestamp":1768521048,"startTime":"0","endTime":"0","summary":"亚盛医药成立于 2009 年，16 年来一直深耕血液瘤领域。在日前举行的第 44 届摩根大通医疗健康年会上，亚盛医药共同创始人、董事长、CEO 杨大俊博士也受邀出席，在主会场就亚盛医药的战略布局、业务进展等发表演讲，引发国际同行的高度关注。成立以来，亚盛始终将血液肿瘤作为核心研究领域。亚盛始终坚守自身战略，不盲目跟随风向。相反，CDE 对这两款药物设定了非常严格的患者入组标准，以确保真正满足临床未满足的需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011608022297a202c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011608022297a202c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","06855","BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2603937939","title":"2026年JPM大会诺华、阿斯利康、辉瑞等巨头超百亿美元交易频现，中国资产成最大赢家","url":"https://stock-news.laohu8.com/highlight/detail?id=2603937939","media":"药厂那点事儿","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603937939?lang=zh_cn&edition=fundamental","pubTime":"2026-01-16 07:05","pubTimestamp":1768518317,"startTime":"0","endTime":"0","summary":"巨头交易频现，中国资产备受青睐。诺华公司周二下午宣布了一项针对中国生物技术公司泽璟生物的许可交易。再生元计划在2026年公布该药用于肥胖治疗的中国3期临床试验结果，并启动全球3期临床开发计划。截至2025年第三季度，19家大型制药公司现金储备总额超过1700亿美元，2025年前三季度产生了约1400亿美元的自由现金流，为大规模并购交易提供了充足的资金支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02359","BK1191","09688","02615","02268","01530","ZLAB","AAPG","06855","02269","01477","06978"],"gpt_icon":0},{"id":"2603386739","title":"JPM2026 | 亚盛医药：多元化管线建设取得突破性进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2603386739","media":"医药魔方Info","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603386739?lang=zh_cn&edition=fundamental","pubTime":"2026-01-15 21:12","pubTimestamp":1768482720,"startTime":"0","endTime":"0","summary":"1月15日，亚盛医药在JPM大会上全面展示了公司2025年在产品商业化、全球临床开发、创新管线拓展及资本市场的里程碑进展，并对2026年的发展进行了展望。奥雷巴替尼2025年继续深化其全球化布局，一线治疗Ph+ ALL患者的全球注册III期临床获得FDA及EMA批准开展。亚盛医药的前沿技术转化与多元化管线建设已取得突破性进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115214635a4c7f403&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115214635a4c7f403&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK1161","AAPG","BK1574"],"gpt_icon":0},{"id":"2603621002","title":"亚盛医药精彩亮相第44届摩根大通医疗健康年会主会场，“全球创新”战略迈入新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2603621002","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603621002?lang=zh_cn&edition=fundamental","pubTime":"2026-01-15 09:16","pubTimestamp":1768439760,"startTime":"0","endTime":"0","summary":"2025年是亚盛医药全球化布局提速的关键一年，我们在产品商业化、全球临床开发、管线创新、资本市场等多维度均实现跨越式突破。展望2026年，'全球创新'战略迈入新阶段，我们将继续以解决全球未满足的临床需求为核心，加速推进这些极具潜力的创新疗法，更好地惠及全球患者。在以患者为中心的全球创新战","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4864009_ZH64009_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE00BLSP4452.SGD","LU0417517546.SGD","LU0868494617.USD","LU1267930490.SGD","IE00BJTD4N35.SGD","LU2756315664.SGD","LU0640476718.USD","LU2106854487.HKD","LU0215105999.USD","BK4585","LU0345770308.USD","LU1551013425.SGD","LU0267386448.USD","LU1974910355.USD","LU0170899867.USD","BK4533","LU2211815571.USD","LU1914381329.SGD","LU2237443895.HKD","LU2381873111.SGD","BK4516","LU2746668974.SGD","LU1668664300.SGD","LU1720051017.SGD","IE00BJLML261.HKD","LU0211328371.USD","LU0345769631.USD","LU1629891620.HKD","SG9999002224.SGD","LU0208291251.USD","IE00BKDWB100.SGD","IE00BN8TJ469.HKD","IE00BKVL7J92.USD","IE0034235303.USD","XLV","LU1280957306.USD","LU0820561818.USD","06855","LABU","LU0942090050.USD","LU0265550946.USD","AAPG","LU2756315318.SGD","LU1496350171.SGD","XBI","LU0106261372.USD","LU0689472784.USD","LU2592432038.USD","LU0345770993.USD","LU1894683348.USD"],"gpt_icon":0},{"id":"2601828013","title":"港股异动 | 亚盛医药-B(06855)涨近4% BTK降解剂APG-3288新药临床申请获美国FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2601828013","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601828013?lang=zh_cn&edition=fundamental","pubTime":"2026-01-07 10:39","pubTimestamp":1767753579,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B(06855)涨近4%，截至发稿，涨3.69%，报53.4港元，成交额6164.18万港元。消息面上，1月7日，亚盛医药官微消息，公司宣布，原创新一代BTK靶向蛋白降解剂 APG-3288的新药临床申请(IND)已获美国FDA许可，将开展其治疗复发/难治B细胞恶性肿瘤的临床研究。这标志着公司在靶向蛋白降解领域的研发成果正式进入临床阶段，是亚盛医药全球创新管线的又一重大布局。该研究是一项全球多中心、开放性的I期临床研究，旨在评估APG-3288治疗复发/难治性血液系统恶性肿瘤患者的安全性、耐受性、PK特征及初步疗效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","LU2125909759.SGD","APG","BK1574","AAPG","BK4129","LU1923622291.USD","BK4139","BK1161","LU2125909916.SGD"],"gpt_icon":0},{"id":"2601824845","title":"亚盛医药BTK降解剂APG-3288的新药临床申请（IND）获美国FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2601824845","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601824845?lang=zh_cn&edition=fundamental","pubTime":"2026-01-07 09:30","pubTimestamp":1767749400,"startTime":"0","endTime":"0","summary":"临床前研究结果显示，与其他在研BTK降解剂相比，APG-3288具更强的BTK降解能力、更高的选择性及更优越的PK特征，呈现潜力5。此次APG-3288的IND获美国FDA许可，是我们在这一领域的重大里程碑。我们将快速推进APG-3288的全球临床开发，积极探索蛋白降解剂这一新分子实体在血液肿瘤及其他BTK相关疾病中的治疗潜力，早日惠及更多患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4858031_ZH58031_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IND","BK1574","BK4139","06855","AAPG","BK4129","LU2125909759.SGD","TK","LU2125909916.SGD","LU1923622291.USD","APG","BK1161","BK4144"],"gpt_icon":0},{"id":"2595713529","title":"亚盛医药-B(06855)：David Sidransky将获委任为首席独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2595713529","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595713529?lang=zh_cn&edition=fundamental","pubTime":"2025-12-30 22:47","pubTimestamp":1767106065,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，Debra Yu博士将获委任为董事会提名委员会新增成员，自2025年12月26日起生效。David Sidransky博士将获委任为首席独立非执行董事，自2025年12月26日起生效，以作为其他董事与本公司股东之间的中间人;及在与董事会主席或本公司管理层的正常沟通渠道不足的情况下，可与其他董事及本公司股东联络。研发委员会将由Marc E. Lippman, MD博士担任主席，由David Sidransky博士及王少萌博士担任成员。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","AAPG","BK1574","BK4139","BK1161"],"gpt_icon":0},{"id":"2592466968","title":"中金:维持亚盛医药-B(06855)“跑赢行业”评级 POLARIS-1欧美获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2592466968","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592466968?lang=zh_cn&edition=fundamental","pubTime":"2025-12-17 11:38","pubTimestamp":1765942705,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持亚盛医药-B“跑赢行业”评级与目标价89港元，公司近期研发进展积极。耐立克一线治疗Ph+ ALL的全球III期研究已获欧美药监机构批准开展，并公布亮眼初步数据；利生妥针对高危基线人群亦显示出良好疗效与安全性，整体研发管线持续兑现，国际化稳步推进。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","AAPG"],"gpt_icon":0},{"id":"2590316821","title":"【直击2025 ASH】亚盛医药耐立克®治疗TKI耐药/不耐受CML-CP患者的注册II期研究4年随访数据亮相，长期疗效和安全性优势再获证实","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316821","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590316821?lang=zh_cn&edition=fundamental","pubTime":"2025-12-09 09:45","pubTimestamp":1765244700,"startTime":"0","endTime":"0","summary":"此次展示的4年随访数据显示，耐立克在TKI耐药/不耐受的CML-CP患者中，持续展现出优于研究者决定的现有最佳可用疗法的显著疗效。值得关注的是，长期随访数据证实其安全性良好，血管闭塞事件发生率为7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4842158_ZH42158_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4016","BK1574","BK4585","AAPG","BK4139","ASH","CP","06855","BK1161","BK4588","LU1261432733.SGD","LU2463526074.USD","BK4109"],"gpt_icon":0},{"id":"2590316824","title":"【直击2025 ASH】亚盛医药耐立克®二线治疗CML-CP临床研究数据更新，更前线治疗潜力明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316824","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590316824?lang=zh_cn&edition=fundamental","pubTime":"2025-12-09 09:34","pubTimestamp":1765244040,"startTime":"0","endTime":"0","summary":"此次公布是对该研究在2024 ASH年会口头报告结果的持续更新，展现了更长时间的随访疗效与安全性特征。此次更新的研究结果进一步提示耐立克有望为二线CML-CP患者带来一种安全有效的治疗选择，尤其对那些一线使用二代BCR-ABL1酪氨酸激酶抑制剂治疗失败的患者。此次数据的更新，进一步体现了耐立克为更广泛的CML患者群体提供安全有效治疗选择的潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4842159_ZH42159_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["AAPG","BK4016","BK4109","LU1261432733.SGD","06855","BK1574","CP","BK4139","LU2463526074.USD","ASH","BK4585","BK1161","BK4588"],"gpt_icon":0},{"id":"2590316827","title":"【直击2025 ASH】亚盛医药耐立克®治疗初治Ph+ ALL患者注册III期研究（POLARIS-1）数据国际首发， 最佳MRD阴性完全缓解率超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316827","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590316827?lang=zh_cn&edition=fundamental","pubTime":"2025-12-09 09:22","pubTimestamp":1765243320,"startTime":"0","endTime":"0","summary":"此次展示的POLARIS-1研究数据体现了耐立克在Ph+ ALL治疗领域的巨大潜力。数据显示，在诱导治疗3个周期内，耐立克联合低强度化疗在初治Ph+ ALL患者中的最佳微小残留病阴性率和MRD阴性完全缓解率分别为66.0%和64.2%；同时显示出良好的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4842157_ZH42157_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","LU1699723380.USD","BK4107","BK4109","LU2355687059.USD","ALL","ASH","BK4139","LU1571399168.USD","BK4533","LU2463526074.USD","BK4134","AAPG","06855","LU0985320562.USD","BK4585","BK1574","BK4588","III"],"gpt_icon":0},{"id":"2590236472","title":"亚盛医药的“底牌”","url":"https://stock-news.laohu8.com/highlight/detail?id=2590236472","media":"药渡Daily","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590236472?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 18:11","pubTimestamp":1765188681,"startTime":"0","endTime":"0","summary":"两大王牌产品的成功，成为亚盛医药快速成长的核心“底牌”。从血液肿瘤到实体瘤，从中国市场到全球舞台，亚盛医药更大的“底牌”正在翻开。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208214536a43b9611&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208214536a43b9611&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","AAPG","BK4139","ASPHF"],"gpt_icon":0},{"id":"2589848384","title":"【直击2025 ASH】亚盛医药Bcl-2抑制剂利生妥®治疗维奈克拉经治髓系肿瘤患者的Ib/II期研究数据积极，全球竞争力持续显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2589848384","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589848384?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 09:58","pubTimestamp":1765159080,"startTime":"0","endTime":"0","summary":"此次数据进一步验证了利生妥在恶性髓系肿瘤领域所具备的稳健疗效与良好安全性。利生妥是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复癌细胞的正常凋亡过程，从而达到治疗肿瘤的目的。期待利生妥在未来，能为髓系恶性肿瘤治疗领域带来新的突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4841048_ZH41048_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","ASH","06855","BK4139","BK4109","LU2463526074.USD","BK1574","AAPG"],"gpt_icon":0},{"id":"2589487292","title":"【直击2025 ASH】突破BTKi耐药和复杂核型的困境！亚盛医药口头报告利生妥®中国关键注册研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2589487292","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589487292?lang=zh_cn&edition=fundamental","pubTime":"2025-12-07 17:11","pubTimestamp":1765098660,"startTime":"0","endTime":"0","summary":"此项关键研究支持了利生妥于2025年7月获中国国家药品监督管理局批准上市。ASH年会是全球血液学领域规模最大的国际学术盛会之一，汇集了最前沿的研究进展及最新的药物研发数据，展示全球血液学领域的最高学术水平。目前，该药物已在中国获批上市，用于既往经过至少包含BTKi在内的一种系统治疗的成人CLL/SLL患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4840909_ZH40909_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4109","ASH","06855","BK4139","BK1574","BK1161","LU2463526074.USD","AAPG"],"gpt_icon":0},{"id":"2589519008","title":"港股异动 | 亚盛医药-B(06855)涨超6% 耐立克®POLARIS-1研究获美国FDA和欧洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589519008","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589519008?lang=zh_cn&edition=fundamental","pubTime":"2025-12-05 09:33","pubTimestamp":1764898401,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B涨超6%，截至发稿，涨5.67%，报64.2港元，成交额1993.31万港元。消息面上，12月5日，亚盛医药-B发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。作为耐立克在欧美监管机构获批的第二个全球注册III期研究，POLARIS-1研究在多国家多中心同步入组，将加速耐立克全球特别是欧美市场的上市进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","EMA","BK1161","BK4139","BK1574","BK4081","06855"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}]}}